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Abstract
Background: Rotavirus gastroenteritis (RGE) is the leading cause of diarrhea in young children in Oman, incurring
substantial healthcare and economic burden. We propose to formally assess the potential cost effectiveness of
implementing universal vaccination with a pentavalent rotavirus vaccine (RV5) on reducing the health care burden
and costs associated with rotavirus gastroenteritis (RGE) in Oman
Methods: A Markov model was used to compare two birth cohorts, including children who were administered the
RV5 vaccination versus those who were not, in a hypothetical group of 65,500 children followed for their first
5 years of life in Oman. The efficacy of the vaccine in reducing RGE-related hospitalizations, emergency department
(ED) and office visits, and days of parental work loss for children receiving the vaccine was based on the results of
the Rotavirus Efficacy and Safety Trial (REST). The outcome of interest was cost per quality-adjusted life year (QALY)
gained from health care system and societal perspectives.
Results: A universal RV5 vaccination program is projected to reduce, hospitalizations, ED visits, outpatient visits and
parental work days lost due to rotavirus infections by 89%, 80%, 67% and 74%, respectively. In the absence of RV5
vaccination, RGE-related societal costs are projected to be 2,023,038 Omani Rial (OMR) (5,259,899 United States
dollars [USD]), including 1,338,977 OMR (3,481,340 USD) in direct medical costs. However, with the introduction of
RV5, direct medical costs are projected to be 216,646 OMR (563,280 USD). Costs per QALY saved would be 1,140
OMR (2,964 USD) from the health care payer perspective. An RV5 vaccination program would be considered cost
saving, from the societal perspective.
Conclusions: Universal RV5 vaccination in Oman is likely to significantly reduce the health care burden and costs
associated with rotavirus gastroenteritis and may be cost-effective from the payer perspective and cost saving from
the societal perspective.
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Background
Rotavirus is the leading cause of severe gastroenteritis in
children under age 5. The virus is responsible for more
than 453,000 (range: 420,000-494,000) deaths each year, of
which more than 90% occur in low-resource countries
[1-3]. Virtually all children will have acquired a rotavirus
infection by the age of 5, regardless of socioeconomic sta-
tus [4,5]. Although occasionally asymptomatic, a rotavirus
infection often results in diarrhea, vomiting, fever and/
or lethargy lasting from a few days to a few weeks [6,7].
Severe episodes of rotavirus gastroenteritis (RGE) are
more likely to involve a combination of these symp-
toms, leading to dehydration if left untreated. Although
deaths are rare in industrialized countries, the health
care burden of RGE-related hospitalizations and emer-
gency department (ED) visits is substantial [8-10]. The
impact of the rotavirus on families of infected children
can be considerable as well [11].
Vaccines to prevent RGE were developed subsequent
to the recognition that wild-type rotavirus infection
induces immunity against subsequent disease [5,12-14].
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Primary rotavirus infections provide substantial protec-
tion against gastroenteritis caused by the same serotype
and against severe disease, regardless of serotype [15].
Since 2006, the World Health Organization (WHO)
has recommended two oral rotavirus vaccines (RotaTeq®
[RV5], Merck & Co.; and Rotarix™; GlaxoSmithKline
Vaccines). Both have positively demonstrated safety and
efficacy in clinical trials and effectiveness profiles, as well
as impact in real world settings [15,16].
In the Sultanate of Oman, data on the burden of rota-
virus were previously analyzed in 2009 by Al Awaidy
et al. [17] In an effort to assess the need for a rotavirus
vaccine, the Oman Ministry of Health had implemented
a nationwide surveillance of severe childhood diarrhea
in under five children at sentinel hospitals in 2006, using
the procedures outlined in the WHO generic protocol
for rotavirus surveillance [17]. Using this surveillance-
based data, Al Awaidy et al. conducted a comprehensive
burden assessment in Oman and concluded that rota-
virus was the single most common cause of diarrhea in
young children, accounting for one-half of all acute
gastroenteritis hospitalizations. Furthermore, an estimated
3,300 rotavirus-associated hospitalizations occur annually
in Oman. An additional 11,500 children receive outpatient
treatment for rotavirus at total annual costs exceeding 2.6
million United States dollars (USD) [17]. The health care
and economic burden associated with rotavirus in Oman
suggested that the introduction of a safe and effective
vaccine can provide considerable benefits from both
payer and societal perspectives.
The purpose of the current study was to assess the
potential cost-effectiveness of implementing universal
RV5 vaccination in Oman, and provide policy makers
with evidence-based information to support the intro-
duction of rotavirus vaccination in the routine infant
immunization program.
Methods
The cost-effectiveness analysis was based on a Markov
model developed in Microsoft Excel [18]. The model
evaluated the cost-effectiveness of universal RV5 vac-
cinations against RGE by tracking a hypothetical birth
cohort of 65,500 children divided into two cohorts: with
and without vaccination during the first 5 years of life.
Although children can acquire multiple rotavirus infec-
tions, the first two infections are believed to be the most
severe based on prospective observational epidemio-
logical studies [5]. Therefore, the model allowed children
to contract up to two symptomatic episodes of RGE,
after which all subsequent infections were assumed to
be asymptomatic.
The model allowed for children to move between dif-
ferent health states over a discrete period of time,
known as a Markov cycle (Figure 1) [19]. For the first
6 months of life, the Markov model used monthly
cycles. Quarterly cycles were employed after 6 months
and through 5 years. Transition probabilities reflected
the likelihood of moving from one health state to
another. Health status reflected whether the child had












Figure 1 Description of the RotaTeq™ Markov model. The model demonstrating the transition cycle for children to move over a Markov
cycle. Note: Markov cycles are monthly through 6 months, quarterly through year 5.
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prior rotavirus infections, serotypes causing the epi-
sodes and whether the child survived the illness.
This manuscript is a cost effectiveness analysis based
on a Markov model and did not involve any experimen-
tal research at all, and does not require approval by IRB.
The epidemiological inputs from Al Awaidy et al 2009
(reference 17), which is an observational prospective sur-
veillance study, had all the necessary ethical approvals.
Analytic perspective and outcome measures
The cost effectiveness analysis assessed the impact of
RV5 vaccinations administered orally in three doses
within the first year of life at ages 2, 4, and 6 months on
the health care and cost burden associated with RGE
among a hypothetical birth cohort of Omani children
age 5 and under. The impact of adding the RV5 vaccine
to routine infant immunizations was quantified as the
net cost per vaccine, as well as the cost per quality-
adjusted life year (QALY) gained from the health care
system and societal perspectives. The health care system
perspective accounted only for direct medical care and
vaccination program costs. The societal perspective
included direct and indirect (e.g., parental work loss to
care for children infected with the rotavirus), medical
and non-medical (e.g., travel to/from health care facil-
ities) costs.
The outcome measure of interest was the QALY
gained by universal vaccination compared to no vaccin-
ation. The QALY is a standardized measure that is
scaled from 0 to 1, with 0 signifying death and 1 signify-
ing perfect health. The QALY incorporates morbidity
and mortality and may be used to compare interventions
across different diseases. The utility weights used to esti-
mate the QALY for each episode of rotavirus were
adapted from a study conducted in Canada and was
based on standard measures that are used to assess
utilities associated with different health states Brisson
et al [20]. The benchmarks used to determine the cost
effectiveness of universal vaccinations were based on
recommendations by the WHO Commission on Mac-
roeconomics and Health, classified as highly cost-effective
if the cost per QALY gained is lower than the per capita
gross domestic product (GDP), possibly cost-effective if
the expenditure is less than 2-3 times the per capita
GDP, and not cost-effective if the cost is higher than 3
times the per capita GDP [21,22]. In Oman, the per
capita GDP in 2010 was 7,938 Omani rial (OMR)
(20,640 USD; 1 OMR = 2.60 USD) [23].
Model inputs
General overview
Table 1 shows the key model inputs with values for the
base case scenario, including ranges for the one-way
sensitivity analysis. All medical and non-medical care
costs are expressed in OMR (and USD) and adjusted
for inflation to 2010 OMR (and USD). The base case
scenario assumed that 94% of children received three
RV5 doses, 3% received two doses, and the remaining 3%
received one dose, based on the immunization coverage
levels of diphtheria, tetanus, and pertussis (DTaP), which
are administered on the same schedule [24].
The size of the birth cohort, based on the Omani Birth
Registry Director General of Planning (DG-PL), was
65,500 [17]. The proportions of all rotavirus infections
and the number of infections for each child were based
on a unique prospective, field-based study conducted
in Mexico by Velazquez et al. documenting all symp-
tomatic and asymptomatic infections among 200 new-
borns [5]. In this landmark study, stool specimens were
collected every 2 weeks for the first 2 years of the chil-
dren's life, and these data provided a comprehensive
description of the natural history of rotavirus infection
in young children. In the Omani economic model,
secondary infection rates were calculated assuming
that nearly 80% of children under age 5 with a primary
infection were at risk of contracting a second infec-
tion. The distribution of primary and secondary infec-
tions by age was based on the surveillance data from
Oman [17].
The efficacy of the vaccine in reducing the number of
RGE-related hospitalizations, ED and office visits and
days of parental work loss for children receiving the
vaccine was based on the results of the Rotavirus Effi-
cacy and Safety Trial (REST) [15,25]. REST was a Phase
III study conducted in 11 countries, enrolling approxi-
mately 70,000 healthy infants. Given that most children
followed the protocol, there are very little data regard-
ing the efficacy for those receiving only one or two
doses. In addition, the majority of serotypes in the trial
were G1-G4 and G9. Thus the efficacy for those with
one and two vaccine doses was based on subsequent
routine effectiveness studies and efficacy for additional
serotypes was assumed to be slightly lower than the effi-
cacy of the 3 dose series based on observational studies
of the effectiveness of RV5 [25]. These assumptions are
described in detail in Itzler et al [18].
Base case scenario
The base case scenario relied on surveillance data pro-
vided by Al Awaidy et al. for the number of hospitaliza-
tions and outpatient office visits, average hospital length
of stay and average medical expenditures for hospitaliza-
tions, and outpatient visits. No information on ED visits
was available in this publication and therefore, informa-
tion from the Parental Burden Survey conducted in Abu
Dhabi, a neighboring country with a similar health care
system, was used to estimate that 14.7% of all health care
encounters in Oman are ED admissions [26]. Death due
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to rotavirus infection was calculated based on a case
fatality rate of 9 per 100,000 children (Table 1) [27].
For an RGE episode resulting in hospitalization or
death, 100% of working parents were assumed to have
missed an average of 2 days of work. For episodes in-
volving ED and office visits, 100% of working parents
were assumed to have missed an average of 1 and
0.50 days of work, respectively.
Direct non-medical costs were assumed to be 12.50
OMR (32.5 USD) and 7.50 (19.5 USD) OMR for rota-
virus episodes resulting in hospitalization/death and all
other episodes, respectively. The cost of a work day
missed was estimated at 11.40 OMR (29.64 USD), and
the price per vaccine dose at 7.69 OMR (19.99 USD).
The QALY lost for each RGE episode used in this
study was 0.0058, based on the Health Utilities Index 2
(HUI2) for children and the EuroQol 5D (EQ5D) ques-
tionnaire for parents from the Measuring the Impact of
Rotavirus Acute Gastroenteritis Episodes (MIRAGE)
study conducted in Canada by Brisson et al. [20].
Sensitivity analyses
Various sensitivity analyses were performed to evaluate
the impact of using different assumptions for health
Table 1 Analysis model inputs
Parameter Base case value (Range for
one-way sensitivity analysis)
Source
Birth cohort 65500 Birth Registry DG-PL
Deaths 6 (4.8,7.2) Al Awaidy 2009, Parashar 2004
Hospitalizations 4279 (3423, 5135) Al Awaidy 2009
ED Visits 3294 (2,635, 3,953) Al Awaidy 2009, Howidi 2012
Office visits 14,838 (11870, 17,806) Al Awaidy 2009, Parashar 2003 &2006
Average hospital length of stay 3 days Al Awaidy 2009
Distribution of health care contacts by type Al Awaidy 20091
Vaccine efficacy (assumed rate reduction) for complete series
Deaths and hospitalizations 88% Vesikari et al. 2006
Office visits 86% Vesikari et al. 2006
Parental work loss Howidi, 2012
Days of work loss for episodes requiring death/hospitalization 2 Assumption
Days of work loss for episodes requiring ED visits 1 Assumption
Days of works loss for episodes requiring office visits 0.50 Assumption
Days of works loss for episodes requiring no care 0.50 Assumption
Percentage of working parents who missed work for episodes involving
deaths/hospitalizations
100% Assumption
Percentage of working parents who missed work for episodes involving
outpatient visits and no care
100% Assumption
Vaccine Coverage 94%: 3 doses, 3%:
2 doses, 3%: 1 dose
WHO
Health care and vaccination costs,OMR [USD]
Hospital day 71 (57, 85) [184.6 (148.2, 221)] Al Awaidy 2009
ED visit 27 (21.6, 32.4) [70.2 (56.16,84.24)] Al Awaidy, 2009
Office visit 27 (21.6, 32.4) [70.2 (56.16,84.24)] Al Awaidy 2009
Day of missed work 11.40 [29.64]
Direct non-medical care for hospitalizations or deaths 12.5 [32.5] Assumption
Direct non-medical care for ED visits 7.5 [19.5] Assumption
Direct non-medical outpatient visits and no care 7.5[19.5] Assumption
Price per dose 7.69 [19.994]
Administration fee per dose 0 Assumption
QALY decrement per rotavirus episode 0.0058 (0.0022, 0.0133) Brisson et al. 2010
ED = emergency department; OMR = Omani rial; USD = United States dollars; QALY = quality-adjusted life year; DG-PL = Omani Birth Registry Director General of
Planning; WHO =World Health Organization.
Exchange rate: 1 OMR = 2.60 USD.
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care utilization, as well as the QALY loss associated
with RGE episodes. One-way sensitivity analyses were
performed for RGE hospitalization frequency and
costs, ED and outpatient visits, death and QALY lost
assumptions.
Additional one-way sensitivity analyses of health care
utilization were also conducted. Estimates for the num-
ber of deaths, hospitalizations and ED and outpatient
visits were evaluated using three scenarios from payer
and societal perspectives: 10%, 25% and 50% fewer than
the base case scenario.
Results
Base case scenario
The model predicted that, with the implementation of
universal vaccination, an 89% reduction in RGE-related
deaths would occur. The universal vaccination program
would also prevent 3,813 hospitalizations, 2,644 ED
visits, 9,886 outpatient visits and 22,200 parental work
days lost due to rotavirus over five years (89%, 80%, 67%,
74% reduction, respectively) (Table 2).
In the absence of a vaccination program, RGE-related
societal costs of care are projected to be 2,023,038 OMR
(5,259,899 USD), including 1,338,977 OMR (3,481,340
USD) in direct medical costs, of which 65% was due to
hospitalization. However, with the introduction of a uni-
versal vaccination program, the model predicts RGE-
related net societal costs in Oman to be 1,909,371 OMR
(4,391,553 USD) and 216,646 OMR (563,280 USD) in
direct medical costs.
The cost effectiveness results of universal vaccination
compared to no vaccination in a single birth cohort in
Oman, from birth through age 5, showed that costs per
QALY saved would be 1,140 OMR (2,964 USD) from the
payer perspective, and cost saving from the societal per-
spective. Specifically, the analysis showed that the cost
would be 13 OMR (33.8 USD) per case avoided and 90
OMR (234 USD) per hospitalization avoided from the
societal perspective (Table 3).
Sensitivity analyses
The results of one-way sensitivity analyses from the
payer and societal perspectives were most sensitive to
the number of hospitalizations and hospitalization costs,
followed by QALY loss per episode, number of out-
patient visits and outpatient visit costs (Figures 2, 3).
The model was least sensitive to the number of ED visits,
ED visit costs.
Additional one-way sensitivity analyses of health care
utilization parameters are reported in Table 4. When the
vaccine administration fee is assumed to be 1.44 OMR/
dose (3.74 USD), the incremental cost effectiveness
ratios (ICERs) are 2,051 OMR (5,333 USD) and 534
OMR (1,388 USD), respectively, from payer and societal
perspectives, which was higher, as expected, compared
to the base case scenario (1,140 OMR [2,964 USD] per
Table 2 Public health and economic impact of a universal vaccination program vs. no vaccination program for base
case scenario
No vaccination program Universal vaccination program Net difference Percent reduction
Events
Deaths 6 0.65 -5 -89.1%
Hospitalizations 4,279 466.06 -3,813 -89.1%
ED visits 3,294 650.01 -2,644 -80.3%
Outpatient visits 14,838 4,951.67 -9,886 -66.6%
Work loss days 30,068 7,867.45 -22,200 -73.8%
Costs, OMR (USD)
Medical care costs 1,338,977 (3,481,340) 216,646 (563,279.6) -1,122,331 (-2,918,061) -83.8%
Hospitalization costs 871,083 (2,264,816) 73,043 (189,911.8) -798,041 (-2,074,907) -91.6%
ED visit costs 85,001 (221,002.6) 16,659 (43,313.4) -68,342 (-177,689) -80.4%
Outpatient visit costs 382,893 (995,521.8) 126,944 (330,054.4) -255,949 (-665,467) -66.8%
Direct non-medical costs 347,527 (903,570.2) 137,216 (356,761.6) -210,311 (-546,809) -60.5%
Indirect (work days lost) costs 336,533 (874985.8) 89,758 (233,370.8) -246,776 (-641,618) -73.3%
Societal costs 2,023,038 (5259,899) 443,619 (1,153,409) -1,579,419 (-4,106,489) -78.1%
Vaccination costs 0 1,465,752 (3,810,955)
Net direct medical care costs 1,338,977 (3,481,340) 1,682,398 (4,374,235) 343,421 (892,894.6) 25.7%
Net societal costs 2,023,038 (5,259,899) 1,909,371 (4,964,365) -113,667 (-295,534) -5.6%
ED = emergency department; OMR = Omani rial; USD = United States dollars.
Exchange rate: 1 OMR = 2.60 USD.
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QALY saved). Sensitivity analyses assuming that health
care utilization (for number of deaths, hospitalization,
ED visits and outpatient visits) were lower by 10%, 25%
and 50% of the base case scenario were cost effective
from the payer and societal perspectives. ICERs had an
increasing trend as expected, with higher costs per
QALY saved using a 50% lower estimation in health care
utilization than for the base case scenario. The sensitivity
analysis assuming 50% fewer hospitalizations than the base
case scenario resulted in ICERs of 2,465 OMR (6,409 USD)
and 1,084 OMR (2,818 USD) from payer and societal per-
spectives, respectively, which were again higher than those
from the payer perspective in the base case scenario, as
expected. Finally, assuming death rates at 50% lower than
the base case scenario resulted in ICERs of 1,527 OMR
(1,970 USD), from the payer’s perspective.
Discussion
Based on a national surveillance study in the Sultanate
Oman, Al Awaidy et al have demonstrated that RGE is the
single most important cause of severe gastroenteritis in
children accounting for almost one-half of all acute
gastroenteritis hospitalizations, with 3,300 hospitalizations
and more than 2.6million USD attributable to RGE.
However, limited data exist on the potential impact of uni-
versal vaccination with rotavirus on the health care and
economic burden in the Sultanate of Oman. The current
study assessed the projected impact of universal vaccin-
ation with RV5 on the health care and economic burden
associated with rotavirus infections in Oman. Results indi-
cate that the introduction of a universal RV5 vaccination
in Oman has the potential to be cost-saving from a soci-
etal perspective and cost-effective from the from the payer
perspective, with an ICER of 1,140 OMR (2,964 USD) per
QALY saved.
The first estimates of health care and economic bur-
den of severe rotavirus infections in pediatric patients in
Oman were provided in a 2009 study by Al Awaidy et al.
Their burden estimates indicated that the Omani gov-
ernment spent an estimated 791,817 USD and 1.8 mil-
lion USD annually to treat rotavirus-associated diarrhea
in outpatient and hospital settings, respectively. The
current model estimates that RGE-related costs of care
are projected to be 2,023,038 OMR (5,259,900 USD)
and confirming the substantial burden of severe rota-
virus on the health care system in Oman.
Al Awaidy et al. indicated the potential positive impact
of rotavirus vaccinations on the substantial burden
Table 3 Cost-effectiveness results for universal vaccination vs. no vaccination in a single birth cohort in Oman from
birth through age 5 (OMR)
Cost effectiveness outcome Payer perspective Societal perspective
Cost per case avoided, OMR (USD) 13 (33.8) Cost saving
Cost per hospitalization avoided, OMR (USD) 90 (234) Cost saving
Cost per QALY saved, OMR (USD) 1,140 (2,964) Cost saving
OMR = Omani rial; USD = United States dollars; QALY = quality adjusted life year.
Exchange rate: 1 OMR = 2.60 USD.
Figure 2 Results of one-way sensitivity analysis: impact of variations in key parameters on ICER, payer perspective. Values varied in
sensitivity analysis indicated by the figures in the brackets. ICER = incremental cost effectiveness ratio; OMR = Omani rial; USD = United States
dollars; QALY = quality-adjusted life year; ED = emergency department. Exchange rate: 1 OMR = 2.60 USD.
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associated with RGE in Oman. Growing evidence from
countries where these vaccinations have been introduced
suggests an association with reduced hospitalizations
and deaths among children under age [1,28-31]. Accord-
ing to recent reports from Europe, Australia and the
United States, reductions of 70% to 95% in the number of
hospitalizations for rotavirus-related diarrhea and 35%
to 48% for all cause-related diarrhea occurred after the
introduction of the vaccine into routine immunization
programs [29-31]. These results are consistent with the
89% reduction in the number hospitalizations following im-
plementation of a universal vaccination program in Oman,
Figure 3 Results of one-way sensitivity analysis: impact of variations in key parameters on ICER, societal perspective.
Table 4 Additional one-way sensitivity analyses for health care utilization parameters
Payer perspective Societal perspective
Scenario Cost/QALY saved OMR (USD) Cost/QALY saved OMR (USD)
Base case scenario 1,140 (2,964) CS
Vaccine administration Fee (1.44 OMR [USD 3.74]) 2,051 (5,332.6) 534 (1,388.4)
Hospitalizations
10% fewer than base case 1,405 (3,653) CS
25% fewer than base case 1,802 (4,685.2) 353 (917.8)
50% fewer than base case 2,465 (6,409) 1,084 (2,818.4)
ED visits
10% fewer than base case 1,163 (3,023.8) CS
25% fewer than base case 1,197 (3,112.2) CS
50% fewer than base case 1,254 (3,260.4) CS
Outpatient visits
10% fewer than base case 1,225 (3,185) CS
25% fewer than base case 1,353 (3,517.8) CS
50% fewer than base case 1,565 (4,069) 48 (124.8)
Deaths
10% fewer than base case 1,201 (3,122.6) CS
25% fewer than base case 1,306 (3,395.6) CS
50% fewer than base case 1,527 (3,970.2) CS
CS = cost saving; ED = emergency department; OMR = Omani rial; USD = United States dollars; QALY = quality adjusted life year.
Exchange rate: 1 OMR = 2.60 USD.
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as predicted in the current study. Oman would be consid-
ered a high-income country based on its per capita GDP, so
parallels to other high-income countries are relevant.
In the current study, although no multiple scenarios
were explored to determine the cost effectiveness of
vaccinations at different prices, one-way sensitivity ana-
lysis demonstrated that with a vaccine administration
fee of 1.44 OMR (3.74 USD), the cost per QALY saved
would be 2,051 OMR (5,333 USD) and 534 OMR (1,388
USD) from the payer and societal perspectives, respect-
ively, and thereby cost-effective from both perspectives.
The number of ED visits was not available from the
current study, and projections were made based on sur-
vey data from Abu Dhabi, UAE, which is a limitation of
this study [26]. Furthermore, there were no published
data available related to indirect costs of the rotavirus
disease; therefore the model assumptions were based on
expert opinion.
Despite these limitations, the current analysis strongly
supports the introduction of routine rotavirus vaccin-
ation in Oman, and provides Omani decision makers
with cost effectiveness information on the implementa-
tion of a universal vaccination program as part of rou-
tine infant immunization programs.
Conclusions
This cost effectiveness model suggests that a universal
RV5 vaccination would have a substantial impact on the
reduction of RGE disease burden in Oman and be a
cost-effective health care intervention from the payer
and cost saving from the societal perspectives. The uni-
versal vaccination program would substantially reduce
the number of hospitalizations, ED and outpatient visits.
When evaluated from a societal perspective, parental
work loss associated with children's RGE episodes is
projected to be substantially reduced as a result of uni-
versal vaccination. These data serve to inform Omani
policy makers in the consideration of a routine rotavirus
vaccination within the standard infant immunization
program as a cost-effective health intervention.
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